RxDoctor Payments Data

Meghan Gregg, NP

Nurse Practitioner · Coeur D Alene, IDNPI 1114438033

Payments from drug & device makers

$763in general payments, 2019–2025

Across 53 payments — averaging $14.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$325
  • BETA Bionics, Inc.$112
  • Medtronic$91
  • Insulet Corporation$60
  • Tandem Diabetes Care, Inc.$56
  • Sequel Med Tech, LLC$33
  • plus $86 from 4 others

What the payments were for

  • Food & beverage$763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$763 in reported general payments places this provider in the 70th percentile of 570 nurse practitioner providers in Idaho.

See all nurse practitioner providers in Idaho

Medicare billing

Part B allowed, 2024
$40,686
Medicare patients
208
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide539$631,893
JardianceEmpagliflozin366$412,902
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7152$184,605
MounjaroTirzepatide142$162,197
TrulicityDulaglutide133$157,343
Tresiba Flextouch U-200Insulin Degludec100$141,081
Tresiba Flextouch U-100Insulin Degludec165$105,116
FarxigaDapagliflozin Propanediol76$62,962
Fiasp FlextouchInsulin Aspart (Niacinamide)51$58,483
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog53$41,704
Humalog Kwikpen U-100Insulin Lispro142$36,572
Lantus SolostarInsulin Glargine,hum.Rec.Anlog224$30,727
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$30,198
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog70$30,065
Humalog Kwikpen U-200Insulin Lispro12$20,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Novolog$31$656,876588 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro, Humulin 70-30$18$346,714397 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 570 nurse practitioner providers in Idaho.

Other nurse practitioner in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →